Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

Scientific reports - 4 Oct 2021

Jung Sangyong, Kim Dong Ha, Choi Yun Jung, Kim Seon Ye, Park Hyojeong, Lee Hyeonjeong, Choi Chang-Min, Sung Young Hoon, Lee Jae Cheol, Rho Jin Kyung

Abstract excerpt

The emergence of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) with activating EGFR mutations is a major hindrance to treatment. We investigated the effects of p53 in primary sensitivity and acquired resistance to EGFR-TKIs in NSCLC cells. Changes in sensitivity to EGFR-TKIs were determined using p53 overexpression or knockdown in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to Epithelial-Mesenchymal Transition

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 34608255
DOI: 10.1038/s41598-021-99267-z
PMCID: PMC8490392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.PMID 34608255Read ↗

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for TherapySemantic proximity Read ↗

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short ReviewSemantic proximity Read ↗

Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.Semantic proximity Read ↗

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIsSemantic proximity Read ↗

Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.Semantic proximity Read ↗

The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer.Semantic proximity Read ↗

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.Semantic proximity Read ↗

Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.Semantic proximity Read ↗

TP53 mutations in nonsmall cell lung cancer.Semantic proximity Read ↗

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

TP63 drives TKI resistance in EGFR-mutant lung cancer via ferroptosis inhibition.Semantic proximity Read ↗

Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.